For many years it has been considered that men with heart failure should avoid taking hormone treatments such as HGH therapy, and especially testosterone therapy. Testosterone Therapy Denver Association is one of the authority sites on this topic. However, from current studies it has been observed that the supplementation of testosterone is useful for both patients with low and normal testosterone levels, although the improvements in those with low levels are greater. This was observed by “Dr. Ferdinando Iellamo,” an assistant professor of internal medicine at Tor Vergata University of Rome, and the lead author of a report in the Journal of the American College of Cardiology, issue of Sept. 1.
The Italian study comprised 70 elderly men with heart failure, all of whom had low levels of testosterone. All received standard heart therapy, but half also received 1,000 milligrammes of long-acting testosterone injections at the beginning, and again at six and 12 weeks. A series of examinations-electrocardiograms, exercise tests and muscle strength assessments-showed improvements in men who received the treatment for hormone replacement therapy but not in those who did not.
The timing and dosage of testosterone therapy can’t be specified for men wsaid.
“Current guidelines are not in place,” he said. “However, our study indicates that long-acting testosterone is safe and well tolerated in patients at the dose and intervals we used [to date used only in patients with hypogonadism].
The study was not designed to determine whether testosterone therapy would prolong the survival of men with failure, Iellamo said. “There is a need for future large trials to properly assess the outcome,” he said.
Men with heart failure who are tempted to try testosterone therapy alone should avoid the temptation, he said. “It is absolutely contraindicated that patients choose testosterone, as well as all drugs, on their own,” Iellamo said. The warning is particularly important for men with high levels of prostate-specific antigen, an indicator of prostate cancer risk, he noted.
“This study confirms our previous findings for a beneficial effect of testosterone in men with moderate chronic heart failure, improved functional exercise capacity and insulin resistance,” said Dr. T. Hugh Jones, an endocrinology consultant at Sheffield University in England.
Jones and his colleagues reported positive results from two studies, one using testosterone injections and the other using a hormone-delivering skin patch.
“Testosterone replacement therapy in men with chronic heart failure has historically been contraindicated,” Jones said. “This was due to the fluid retention observed with older forms of testosterone preparation. Together with our studies this study shows that testosterone is safe in these patients and has an advantage on the underlying condition.
But the case for testosterone therapy in heart failure is far from proven, he said. “Now it is necessary to do long-term studies evaluating effects on survival, quality of life, and longer-term safety to determine whether this treatment should be routinely used in men’s treatment,” Jones said.
Jones also said that the case for testosterone therapy in heart failure is far from being proven. He also said that studies show long-term survival, quality of life and long-term safety need to be done to determine whether this treatment should be routinely used in the treatment of men’s heart failure.